Slate Path Capital LP Alnylam Pharmaceuticals, Inc. Transaction History

Slate Path Capital LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $26.2 Million - $31.3 Million	-213,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$121.19 - $165.49 $45 Million - $61.4 Million	-371,000 Reduced 63.53%	213,000 $31 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $14 Million - $21 Million	-134,000 Reduced 18.66%	584,000 $86.5 Million
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $9.03 Million - $13 Million	-97,000 Reduced 11.9%	718,000 $78.2 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $14.9 Million - $24.8 Million	200,000 Added 32.52%	815,000 $93.9 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $8.89 Million - $12.5 Million	135,000 Added 28.13%	615,000 $44.6 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $9.27 Million - $11.3 Million	105,000 Added 28.0%	480,000 $47.3 Million
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $8.35 Million - $10.7 Million	-72,000 Reduced 16.11%	375,000 $44.7 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $13.1 Million - $16 Million	-114,000 Reduced 20.32%	447,000 $56.8 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $40.7 Million - $66.3 Million	561,000	561,000 $65.9 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Slate Path Capital LP, based on Form 13F filings with the SEC.

Stay updated on Slate Path Capital LP with notifications on news.